Susquehanna International Group’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$331K Buy
25,180
+15,059
+149% +$226K ﹤0.01% 10656
2025
Q4
$156K Buy
+10,121
New +$135K ﹤0.01% 11131
2025
Q3
Sell
-29,197
Closed -$275K 13418
2025
Q2
$325K Buy
29,197
+9,288
+47% +$116K ﹤0.01% 10157
2025
Q1
$245K Buy
19,909
+7,295
+58% +$91.3K ﹤0.01% 10515
2024
Q4
$141K Buy
+12,614
New +$110K ﹤0.01% 11065
2024
Q2
Sell
-203,776
Closed -$2.06M 12858
2024
Q1
$2.69M Buy
203,776
+161,491
+382% +$2.3M ﹤0.01% 4719
2023
Q4
$436K Buy
+42,285
New +$337K ﹤0.01% 9001
2023
Q2
Sell
-14,052
Closed -$65.2K 12793
2023
Q1
$65.2K Buy
+14,052
New +$53.8K ﹤0.01% 11568

Other funds holding NPCE

Susquehanna International Group's NPCE Position: Q1 2026 in Review

Susquehanna International Group increased its Neuropace (NPCE) stake by 149% in Q1 2026, buying an estimated $226K and bringing the position to 25,180 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #10656.

Susquehanna International Group first reported a position in NPCE in Q1 2023 and has held it in 8 quarters since. The position peaked at $2.69M in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Susquehanna International Group held 25,180 shares of Neuropace worth $331K as of Q1 2026.
  • Susquehanna International Group bought 15,059 Neuropace shares in Q1 2026, an estimated $226K.
  • Neuropace made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10656 holding.
  • Susquehanna International Group first reported a position in Neuropace in Q1 2023 and has held it in 8 quarters since.
  • Susquehanna International Group's Neuropace position peaked at $2.69M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.